Castle Biosciences Inc

Change company Symbol lookup

Select an option...

CSTL Castle Biosciences Inc

GIC Global Industrial Co

EQHA EQ Health Acquisition Corp

DLCAW Deep Lake Capital Acquisition Equity Warrant Exp 04 Jan 2026 *W EXP 01/04/2026

CDK CDK Global Inc

CNC Centene Corp

ONXXF Ontex Group NV

INDB Independent Bank Corp (Massachusetts)

IIII Insu Acquisition Corp III

BOOT Boot Barn Holdings Inc

Go

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. Its products include DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, TissueCypher and IDgenetix. DecisionDx-Melanoma is a gene expression profile test developed to identify the risk of metastasis in patients with invasive cutaneous melanoma.